1. Home
  2. IDYA vs SXI Comparison

IDYA vs SXI Comparison

Compare IDYA & SXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • SXI
  • Stock Information
  • Founded
  • IDYA 2015
  • SXI 1955
  • Country
  • IDYA United States
  • SXI United States
  • Employees
  • IDYA N/A
  • SXI N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • SXI Industrial Machinery/Components
  • Sector
  • IDYA Health Care
  • SXI Industrials
  • Exchange
  • IDYA Nasdaq
  • SXI Nasdaq
  • Market Cap
  • IDYA 2.3B
  • SXI 2.4B
  • IPO Year
  • IDYA 2019
  • SXI N/A
  • Fundamental
  • Price
  • IDYA $27.16
  • SXI $209.23
  • Analyst Decision
  • IDYA Buy
  • SXI Strong Buy
  • Analyst Count
  • IDYA 14
  • SXI 4
  • Target Price
  • IDYA $49.17
  • SXI $223.50
  • AVG Volume (30 Days)
  • IDYA 953.6K
  • SXI 114.3K
  • Earning Date
  • IDYA 11-03-2025
  • SXI 10-28-2025
  • Dividend Yield
  • IDYA N/A
  • SXI 0.62%
  • EPS Growth
  • IDYA N/A
  • SXI N/A
  • EPS
  • IDYA N/A
  • SXI 4.64
  • Revenue
  • IDYA $7,000,000.00
  • SXI $790,107,000.00
  • Revenue This Year
  • IDYA $62.30
  • SXI $14.61
  • Revenue Next Year
  • IDYA $285.58
  • SXI $7.59
  • P/E Ratio
  • IDYA N/A
  • SXI $44.63
  • Revenue Growth
  • IDYA N/A
  • SXI 9.64
  • 52 Week Low
  • IDYA $13.45
  • SXI $128.85
  • 52 Week High
  • IDYA $39.30
  • SXI $212.66
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 70.30
  • SXI 64.56
  • Support Level
  • IDYA $24.04
  • SXI $197.00
  • Resistance Level
  • IDYA $25.39
  • SXI $211.93
  • Average True Range (ATR)
  • IDYA 1.05
  • SXI 4.58
  • MACD
  • IDYA 0.16
  • SXI -1.45
  • Stochastic Oscillator
  • IDYA 99.45
  • SXI 79.31

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

Share on Social Networks: